ArticleAdvanced biomedical research2018
Levofloxacin-containing versus Clarithromycin-containing Therapy for
Article in Advanced biomedical research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07021729 (Comparison of Conventional Clarithromycin Vs Alternative Levofloxacin Based Regimen in Treatment of Helicobacter Pylori Infection), which is not on this map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparison of Conventional Clarithromycin Vs Alternative Levofloxacin Based Regimen in Treatment of Helicobacter Pylori Infection
Who cites it
6 citing papers in PubMed, 9 citations in OpenAlex.
- Is tailored therapy based on antibiotic susceptibility effective ? a multicenter, open-label, randomized trial.Frontiers of medicine · 2020Trial
- An Update on Eradication ofMiddle East journal of digestive diseases · 2024Review
- Susceptibility-guided vs. empirical 10-day quadruple treatment forFrontiers in microbiology · 2022Article
- The Efficacy, Safety, and Tolerability of Levofloxacin Quadruple Therapy forEvidence-based complementary and alternative medicine : eCAM · 2022Article
- Clinical Effect of Clarithromycin Combined with Tinidazole on Helicobacter pylori-Related Gastritis and Its Influence on COX-2 Expression.BioMed research international · 2021Article
- Response to "Levofloxacin-containing versus Clarithromycin-containing Therapy forAdvanced biomedical research · 2018Article
Corrections and comments
- Commented on by
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study evaluated the clinical efficacy and tolerability of a 14-day course of bismuth-based quadruple therapy including tinidazole and levofloxacin in compare to a 14-day bismuth-based quadruple therapy including clarithromycin as first-line treatment for MATERIALS AND
methodsThe study was a prospective, parallel group, randomized controlled, clinical trial that conducted on 150 patients with
resultsThe eradication rates for PBAC regimen was 81.1% (95% confidence interval [CI]: 71.9-90.2) and for PBATL regimen was 70.8% (95% CI: 60.1-81.6), which was not significantly different (
conclusionThere is no significant difference between PBAC and PBATL regimen, and efficacy was similar in both groups. The overall rate of treatment failure suggests that up to 18%-30% of patients will fail bismuth-based quadruple therapy and require retreatment for the infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.